AU2001228625A1 - Composition of antigen and glycolipid adjuvant sublingual administration - Google Patents

Composition of antigen and glycolipid adjuvant sublingual administration

Info

Publication number
AU2001228625A1
AU2001228625A1 AU2001228625A AU2862501A AU2001228625A1 AU 2001228625 A1 AU2001228625 A1 AU 2001228625A1 AU 2001228625 A AU2001228625 A AU 2001228625A AU 2862501 A AU2862501 A AU 2862501A AU 2001228625 A1 AU2001228625 A1 AU 2001228625A1
Authority
AU
Australia
Prior art keywords
antigen
composition
sublingual administration
glycolipid adjuvant
glycolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228625A
Other languages
English (en)
Inventor
Christopher Wallace Cluff
Garry Elliott
Alan Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergy Therapeutics UK Ltd
Corixa Corp
Original Assignee
Allergy Therapeutics UK Ltd
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9883730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001228625(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergy Therapeutics UK Ltd, Corixa Corp filed Critical Allergy Therapeutics UK Ltd
Publication of AU2001228625A1 publication Critical patent/AU2001228625A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2001228625A 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration Abandoned AU2001228625A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000891.2A GB0000891D0 (en) 2000-01-14 2000-01-14 Formulation
GB0000891 2000-01-14
PCT/GB2001/000142 WO2001051082A1 (en) 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration

Publications (1)

Publication Number Publication Date
AU2001228625A1 true AU2001228625A1 (en) 2001-07-24

Family

ID=9883730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228625A Abandoned AU2001228625A1 (en) 2000-01-14 2001-01-15 Composition of antigen and glycolipid adjuvant sublingual administration

Country Status (15)

Country Link
US (1) US8470331B2 (ja)
EP (3) EP2100616B1 (ja)
JP (1) JP4648603B2 (ja)
AR (1) AR027924A1 (ja)
AU (1) AU2001228625A1 (ja)
CA (1) CA2397359C (ja)
CZ (1) CZ304941B6 (ja)
DE (1) DE60139305D1 (ja)
DK (1) DK2100616T3 (ja)
ES (2) ES2328336T5 (ja)
GB (2) GB0000891D0 (ja)
HU (1) HU230545B1 (ja)
PL (1) PL356963A1 (ja)
SK (1) SK288411B6 (ja)
WO (1) WO2001051082A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052757A1 (en) * 1996-06-04 2006-03-09 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with analgesic or anesthetic
US20060025726A1 (en) * 1996-06-04 2006-02-02 Vance Products Incorporated, D/B/A Cook Urological Incorporated Implantable medical device with pharmacologically active layer
US20060030826A1 (en) * 1996-06-04 2006-02-09 Vance Products Incorporated,d/b/a Cook Urological Incorporated Implantable medical device with anti-neoplastic drug
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
MXPA05005528A (es) 2002-11-26 2006-04-05 Alk Abello As Producto farmaceutico de alergeno.
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
WO2005115449A1 (en) * 2004-05-28 2005-12-08 Alk-Abelló A/S Method of treating allergy and infection by eliciting an iga antibody response
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
EP2425242B1 (en) * 2009-04-29 2019-06-05 Pravin K. Muniyappa Device and method for the diagnosis of gastrointestinal allergy
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
KR102151962B1 (ko) 2020-03-24 2020-09-04 안병철 어린 포유동물의 전염성 질병을 예방 또는 치료하기 위한 혈청 조성물의 제조방법, 상기 방법에 의해 제조된 혈청 조성물 및 이의 용도
EP4129309A4 (en) * 2020-03-24 2023-11-01 Byung Chul Ahn METHOD FOR PRODUCING A SERUM COMPOSITION FOR THE PREVENTION OR TREATMENT OF AN INFECTIOUS DISEASE ASSOCIATED WITH THE MUCOSA IN YOUNG MAMMALS, SERUM COMPOSITION THUS PRODUCED AND CORRESPONDING USE

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128637A (en) 1966-09-13 1968-09-25 Beecham Group Ltd Influenza vaccine
US3541201A (en) 1968-12-18 1970-11-17 Ethan Alan Brown Novel sodium chloride encapsulated injectionable substances
GB1377074A (en) 1971-07-13 1974-12-11 Beecham Group Ltd Process for preparing injectable compositions
GB1492973A (en) 1974-02-16 1977-11-23 Beecham Group Ltd Process for preparing injectable compositions
US4070455A (en) 1974-02-16 1978-01-24 Beecham Group Limited Process for preparing injectable desensitizing compositions and products thereof in microparticle form
EP0182442B2 (en) 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5244663A (en) * 1987-01-28 1993-09-14 Medibrevex Therapeutic method against allergy
US4975420A (en) 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
FR2621916B1 (fr) 1987-10-19 1990-03-09 Bioeurope Derives de la l-tyrosine solubles dans l'eau et procede pour leur preparation
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
KR950700083A (ko) * 1992-03-03 1995-01-16 스즈키 다다시 경구용 백신(oral vaccine)
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
JPH08508247A (ja) * 1993-03-11 1996-09-03 セクレテック，インク． 粘膜表面への免疫原の輸送における重合的粘膜付着体
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
PT705109E (pt) * 1993-05-25 2001-02-28 American Cyanamid Co Adjuvantes para vacinas contra virus sinciciais respiratorios
AU7482694A (en) * 1993-08-27 1995-03-21 Enteric Research Laboratories, Inc. (campylobacter jejuni) antigens, and methods for their production and use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5646115A (en) 1994-10-07 1997-07-08 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
WO1996025664A1 (en) * 1995-02-17 1996-08-22 Immunotherapy, Inc. Immunotherapy screening, prognosis, and treatment methods and compositions
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
GB9508785D0 (en) 1995-04-29 1995-06-21 Smithkline Beecham Plc Novel compositions
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US5973128A (en) * 1996-11-22 1999-10-26 The Hospital For Sick Children Research And Development Lp Glycolipid mimics and methods of use thereof
WO1998040097A2 (en) 1997-03-10 1998-09-17 Bayer Corporation Bovine respiratory and enteric coronavirus as a vaccine
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
WO1998058956A2 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Methods for inducing an immune response involving prime-boost protocols
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
AU750173B2 (en) 1997-11-10 2002-07-11 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
WO1999064074A1 (en) * 1998-06-11 1999-12-16 The Trustees Of The University Of Pennsylvania Methods and compositions for delivering proteins to macrophage cells and cells of macrophage derived lineage
CA2330209A1 (en) 1998-06-12 1999-12-23 Smithkline Beecham Biologicals S.A. Recombinant production of toxoplasma sag1 antigen
CA2337823A1 (en) 1998-06-26 2000-01-06 Bernard Meignier Mucosal targeting immunisation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
ATE481108T1 (de) 1999-02-26 2010-10-15 Novartis Vaccines & Diagnostic Verwendung von bioadhaesiven und adjuvantien für die mukosale anwendung von antigenen
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
AU777952B2 (en) 1999-04-23 2004-11-04 Pharmexa A/S Method for down-regulating IL5 activity
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU5731200A (en) 1999-06-11 2001-01-02 Endorex Corporation Adjuvant-containing polymerized liposomes for oral, mucosal or intranasal vaccination
GB9924529D0 (en) 1999-10-15 1999-12-15 Smithkline Beecham Biolog Novel compounds
EP1289530B1 (en) * 2000-06-14 2006-10-04 PORTER, William Leslie Lipids for modulating immune response
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition

Also Published As

Publication number Publication date
GB0000891D0 (en) 2000-03-08
JP4648603B2 (ja) 2011-03-09
EP1255563B2 (en) 2016-03-02
HUP0203972A2 (hu) 2003-03-28
PL356963A1 (en) 2004-07-12
CA2397359C (en) 2012-06-05
CZ304941B6 (cs) 2015-02-04
DK2100616T3 (en) 2016-02-08
JP2003519669A (ja) 2003-06-24
GB2360210B (en) 2004-12-15
EP1255563A1 (en) 2002-11-13
HU230545B1 (hu) 2016-11-28
HUP0203972A3 (en) 2011-02-28
EP2100616A3 (en) 2009-09-23
EP1255563B1 (en) 2009-07-22
AR027924A1 (es) 2003-04-16
CZ20022417A3 (cs) 2003-03-12
US8470331B2 (en) 2013-06-25
EP2100616B1 (en) 2015-11-25
ES2561360T3 (es) 2016-02-25
EP2100616A2 (en) 2009-09-16
ES2328336T3 (es) 2009-11-12
SK288411B6 (sk) 2016-10-03
US20030165512A1 (en) 2003-09-04
CA2397359A1 (en) 2001-07-19
SK10412002A3 (sk) 2003-05-02
EP2322212A1 (en) 2011-05-18
ES2328336T5 (es) 2016-06-21
GB2360210A (en) 2001-09-19
GB0101035D0 (en) 2001-02-28
WO2001051082A1 (en) 2001-07-19
DE60139305D1 (de) 2009-09-03

Similar Documents

Publication Publication Date Title
AU2001228625A1 (en) Composition of antigen and glycolipid adjuvant sublingual administration
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
EP1291377B8 (en) Silicone compound and cosmetic preparation
AU2001291859A1 (en) Use of copolycarbonates
AU2002225855A1 (en) Preparation of nanocrystallites
AU2001270057A1 (en) Acoustical and thermal insulator
HUP0200815A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU4139801A (en) Controlled delivery of antigens
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001290239A1 (en) Medicinal composition
AU2001241159A1 (en) Silicone gel composition
AU6902901A (en) Synchronisation of databases
AU2001284763A1 (en) Preparation of risperidone
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
AU2002216847A1 (en) Epitopes of pai-1
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001245950A1 (en) Preparation of deoxynucleosides
SI1187629T1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
AU2001267541A1 (en) Vaccine composition
AU2001279729A1 (en) Use of cross-linker and compositions made therefrom
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2001263511A1 (en) Alkyl glycidyl carbonate compositions and their preparation
AU2001267613A1 (en) Adjuvant composition comprising FHA protein or fragment of FHA protein in free form
AUPQ760400A0 (en) Herbical formulations and methods of use thereof